CLOSE
SITE MAP
イノベーションが
生まれる「まち」。

2020/11/06

Shinichiro Takezawa, Ph.D., CEO, Setsurotech Inc.

Accelerate PDCA cycle for drug discovery with disease models

Shinichiro Takezawa, Ph.D., CEO, Setsurotech Inc.

WEB写真(セツロテック様).jpg

[Summary]
Various disease model animals are used in drug development and disease research in pharmaceutical companies. In order to improve the accuracy, there is an increasing demand for models according to human genotypes, such as humanizing the target gene of mice. In addition to animal models, there is a need to individually modify the genotypes of cultured cells and iPS cells, and it is expected that demand for fast and low price custom-made disease model creation services will increase.

We will develop a contract service that utilizes genome editing technology that can freely modify the targeted gene in experimental animals and cultured cells. In particular, utilizing the CRISPR / Cas9 technology from the United States, high-efficiency genome-editing mouse production by the fertilized egg electroporation method invented at Tokushima University, and high-efficiency genome-editing cultured cell production by the VIKING method invented at Tokushima University. We have strengths in and provide fast and low price disease models.

It is estimated that there are about 80 major companies developing drugs in Japan, and about 200 including startups. In Asia as a whole, it is estimated to be about three times that number, and it is estimated to be about 600 companies including startups. According to a survey by MarketsandMarkets, the size of the mouse model market is equivalent to 165.4 billion yen worldwide. The market size of the rat model is 39.8 billion yen worldwide according to a survey by Global Information, Inc. In addition, the cultured cell model is estimated by us to be 40 billion yen worldwide. In addition, some animals such as pigs and monkeys and disease models are also used. Together, the disease model market is estimated to be around 300 billion yen worldwide. Of that, Asia will account for about 40%. It is assumed that there is an Asian market for disease model animals of 160 billion yen. It is estimated that 5% of the total in Japan, about 15 billion yen. The market growth rate is estimated to be 7.5% to 9.6% according to a survey by MarketsandMarkets and Global Information.

Major awards
Technology Commercialization Program (TCP) NEDO 2016 Grand Prize
The 13th Japan New Business Creation Award <Entrepreneur Category> Japan New Business Council Federation 2018 Excellence Award
Shikoku Industrial Technology Award General Incorporated Foundation Shikoku Industry and Technology Promotion Center (STEP) 2020 Encouragement Award


[Profile]
He has a PhD in molecular biology. After that, he worked for a management consulting company and started a science media company. After the business succession of a media company, he set up Seturo Tech for the third time.